Efficacy of QR678 Neo^® hair growth factor formulation for the treatment of hair loss in Covid‐19‐induced persistent Telogen Effluvium—A prospective, clinical, single‐blind study

Abstract

Background Telogen Effluvium (TE) in a post‐Covid‐19 patient causes excessive shedding of hair. No definite treatment is available till now. Past studies demonstrates that QR678Neo® has shown promising results in various types of Alopecia. Aim In this study, we aim to establish efficacy of QR678 Neo® hair growth factor formulation administration in Covid‐19‐induced persistent TE for treatment of hair loss and for hair regrowth. Material & Method Twenty adult patients (all females) presenting with persistent TE starting few weeks after recovery from Covid‐19 infection, and continuing beyond 6 months were included for the study. A 1.5 mL solution of QR678 Neo® hair growth factor formulation was administered in the scalp per session. A total of 8 sessions (one session every 4 weeks) were done. The results were assessed at the baseline, after 4thsession, and 1 month after 8th session. Results Most of the patients showed significant reduction in hair fall; 89% patients showed excellent hair growth. Global photographic assessment score showed marked improvement, which maintained even post therapy. Videomicroscopic assessment showed increase in the hair count (mean =29.32) after 8th session, that further improved even post therapy. The subjective assessment scores for overall hair growth, appearance of hair, reduction in visibility of the scalp, and hair loss were 4, 4.5, 4.25, and 5, respectively. Conclusion Management of Covid‐19‐induced persistent Telogen Effluvium has been unclear and futile so far. Intra‐dermal administration of QR678 Neo® hair growth factor formulation in the scalp, reduces hair fall, improves hair regrowth, and increases the hair density.

A newer approach in the treatment of seborrheic dermatitis with QR678® and QR678 Neo®—A prospective pilot study

“…Apart from these, the growth factor formulation has also shown clinically significant results in higher grades of alopecia 46. A clinically significant hair growth was also seen when QR678 Neo® was administered in patients suffering from alopecia areata and post infection acute hairfall 47,48. The efficacy of QR678 Neo® was investigated in conjunction with dermaroller application and its performance was evaluated in comparison to both intradermal and topical administrations.…”

Evaluation of the safety and effectiveness of intradermal administration of QR678 Neo® hair growth factor formulation: A phase‐IV, open‐label, single‐arm multi‐ethnicity clinical trial

“…QR678 Neo ® has been also researched in cases of Covid‐19 induced persistent Telogen Effluvium and has been found to be effective in controlling hair loss, improving hair count and hair re‐growth 39 …”

The iceberg phenomenon of alopecia associated public health ramifications on the quality of life among adults in India

“…With alopecia being labeled as a “Cosmetic Concern” and having not recognized its implications on mental health and quality of life, the treatment modalities so available seem restricted in terms of sensitivity and economy 29 . ‐ 30 In several countries, including India, getting hairloss treatment or seeking cure for alopecia is still considered as an ‘elective procedure’, with a considerable surcharge (such as Goods and Services tax) levied by the government on such treatments/procedures. Untreated alopecia can be reminscent of past distress related episodes ‐ chemotherapy induced alopecia as well as alopecia secondary to Poly Cystic Ovarian Syndrome 31 .…”